Reuters logo
BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial
2017年10月16日 / 下午2点52分 / 1 个月前

BRIEF-TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial

Oct 16 (Reuters) - TG Therapeutics Inc:

* TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial

* TG Therapeutics Inc - ‍targeting an NDA/BLA filing for combination of TGR-1202 + TG-1101 in 2H18​

* TG Therapeutics Inc - ‍top-line ORR data from UNITY-CLL trial expected in 2Q18​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below